source
- Amylyx reports Phase 3 success for avexitide in post-bariatric hypoglycemiaAmylyx announced a late-stage success for avexitide, a GLP-1 receptor antagonist, in a Phase 3 trial targeting post-bariatric hypoglycemia. The trial results showed the drug achieved its primary e…
- STAT+: Amylyx endocrine drug succeeds in pivotal studyIn a Phase 3 trial of people with post-bariatric hypoglycemia, those taking the drug, avexitide, experienced a 55% reduction in the rate of serious low blood sugar events compared with…STAT · 1h ago↗ source